Camber
-12%
est. 2Y upside i
Camber is on a mission to revolutionize the healthcare reimbursement system by reducing the significant administrative burden on healthcare clinics and families. Camber’s proprietary platform increases the speed, accuracy and efficiency of healthcare claims processing and payments, enabling providers to deliver high quality healthcare to more patients.
Rank
#2588
Sector
Healthcare Technology
Est. Liquidity
~5Y
Data Quality
Data: LowBased on available data, the expected 2-year upside is negative (-12%) due to high entry multiple and severe preference overhang.
Last updated: July 3, 2026
In a bullish scenario, Camber achieves an IPO or category leadership, supporting a 10x exit multiple on projected $28.93M revenue, yielding ~$289M exit. After 20pp dilution, net upside 72.9%.
Base case converges multiple to 6x, yielding ~$174M exit, but after dilution net downside 4.3%.
Bear case multiple compresses to 3x due to incumbent competition, exit ~$87M, after dilution net downside 62.1%.
Preference Stack Risk
severeFunding Intensity
33%Total funding of $50M represents 33% of estimated $150M valuation, so preferred shares have significant liquidation preference.
Dilution Risk
highWith ~15 months runway from Feb 2025 raise, a follow-on round within 2 years is likely, diluting common by 15-25%.
Secondary Liquidity
noneNo secondary trading reported; liquidity likely only via exit.
Questions to Ask at the Interview
Strategic questions based on Camber's data — designed to show you've done your homework.
- 1
“How does Camber's AI moat defend against large incumbents like Waystar?”
- 2
“What is the primary unit economics and what drives margin expansion?”
- 3
“Given the preference stack, what is your expected time to liquidity and the typical outcome for common stock?”
Community
Valuation Sentiment
Our model estimates -12% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.